|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Assets: | ||||||||||||||||||
| Cash | ||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||
| Accounts receivable | ||||||||||||||||||
| Other receivable | ||||||||||||||||||
| Inventory | ||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||
| Derivative asset | ||||||||||||||||||
| Deferred offering costs | ||||||||||||||||||
| Other current assets | ||||||||||||||||||
| Total Current Assets | ||||||||||||||||||
| Cash and investments held in the Trust Account | ||||||||||||||||||
| Property and Equipment, net of depreciation | ||||||||||||||||||
| Other assets | ||||||||||||||||||
| Patents, net of amortization | ||||||||||||||||||
| Total Assets | ||||||||||||||||||
| Current Liabilities: | ||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||
| Income taxes payable | ||||||||||||||||||
| Excise tax payable | ||||||||||||||||||
| Over-allotment liability | ||||||||||||||||||
| Funds allocated for share redemption | ||||||||||||||||||
| Derivative liabilities | ||||||||||||||||||
| Due to related party | ||||||||||||||||||
| Related Party | ||||||||||||||||||
| Convertible note – Related Party | ||||||||||||||||||
| Related Party | ||||||||||||||||||
| Total convertible note – Related Party | ||||||||||||||||||
| Convertible note payable – Sponsor | ||||||||||||||||||
| Sponsor | ||||||||||||||||||
| Total convertible note payable – Sponsor | ||||||||||||||||||
| Total Current Liabilities | ||||||||||||||||||
| Deferred underwriting commission | ||||||||||||||||||
| Convertible notes | ||||||||||||||||||
| Short-term notes payable | ||||||||||||||||||
| Short-term notes payable – related party | ||||||||||||||||||
| Total Liabilities | ||||||||||||||||||
| Class A common stock subject to possible redemption; 2,293,741 and 12,350,000 shares (at redemption value) | ||||||||||||||||||
| Stockholders’ Equity (Deficit): | ||||||||||||||||||
| Common stock, $0.0001 par value, 300,000,000 shares authorized, 8,512,771 and 7,465,283 issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||
| Class A Common Stock | ||||||||||||||||||
| Class B Common Stock | ||||||||||||||||||
| Total common stock, $0.0001 par value, 300,000,000 shares authorized, 8,512,771 and 7,465,283 issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||
| Class B common stock, $0.0001 par value, 10,000,000 shares authorized, 3,087,500 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively | ||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||
| Stock subscription receivable | ||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||
| Total accumulated deficit | ||||||||||||||||||
| Total Stockholders’ Equity (Deficit) | ||||||||||||||||||
| Total Liabilities and Stockholders’ Equity (Deficit) | ||||||||||||||||||
Loading...
